- Bicycle Therapeutics currently has 5 oncology candidates in development
- The company also has development projects underway outside of the oncology arena
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles product platform, announced on 11/14/18 that it has been recognized at the 2018 World ADC (antibody drug conjugates) Awards, held during the World ADC Conference in San Diego, Calif., as Best New Drug Developer.
The award honors a company in the drug conjugate field that has made strong progress advancing its preclinical pipeline. Earlier this year, Bicycle entered the clinic with its lead Bicycle Toxin Conjugate™ candidate, BT1718, initiating a Phase 1/11a study as part of its partnership alliance with Cancer Research UK. The company is also advancing a robust preclinical pipeline of Bicycle Toxin Conjugates, Bicycle Targeted Immune Activators and Bicycle T-Cell Modulators.
“Bicycles and Bicycle Toxin Conjugates represent the next generation of drug conjugates which exhibit completely different properties to ADCs. It is particularly pleasing for Bicycle Therapeutics that the ADC community continues to recognize the potential of our non-antibody containing conjugates that deliver toxins using a combination of fast in / fast out pharmacokinetics, extracellular toxin release within the tumor microenvironment and renal elimination,” said Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer. “This award highlights the giant strides made by our scientific and clinical teams to develop a broad pipeline of Bicycle conjugates and advance them into the clinic to develop medicines for diseases with high unmet clinical need.”
The company currently has five oncology candidates in development. In addition to its oncology programs, Bicycle has development programs in: respiratory & cardiometabolic disease, rare non-malignant haematology, ophthalmology, and anti-infectives.